These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104. Analysis of Panel Reactive Antibodies in Renal Transplant Recipients Detected by Luminex: A Single-Center Experience. İnal A; Özçelik Ü; Ogan Uyanık E; Külah E; Demirağ A Exp Clin Transplant; 2016 Aug; 14(4):401-4. PubMed ID: 26517205 [TBL] [Abstract][Full Text] [Related]
105. Pre-transplant crossmatch-negative donor-specific anti-HLA antibody predicts acute antibody-mediated rejection but not long-term outcomes in kidney transplantation: an analysis of the Korean Organ Transplantation Registry. Lee H; Lee H; Sun IO; Park JH; Park JW; Ban TH; Yang J; Kim MS; Yang CW; Chung BH; Front Immunol; 2024; 15():1420351. PubMed ID: 39055708 [TBL] [Abstract][Full Text] [Related]
106. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395 [TBL] [Abstract][Full Text] [Related]
107. Frequency of Human Leukocyte Antigens and Donor Specific Antibodies in Long-Term Living Donor Kidney Transplantation. Alagoz S; Seyahi N Transplant Proc; 2019 Sep; 51(7):2302-2307. PubMed ID: 31358448 [TBL] [Abstract][Full Text] [Related]
108. Human Leukocyte Antigen Compatibility and De Novo Donor-Specific Antibodies in Long-term Renal Transplant Patients With Stable Graft Function. Kasimatis E; Fylaktou A; Karampatakis T; Schoina M; Zarras C; Anastasiou A; Papachristou M; Boukla A; Daoudaki M; Fouzas I; Papagianni A Transplant Proc; 2019 Mar; 51(2):413-415. PubMed ID: 30879554 [TBL] [Abstract][Full Text] [Related]
109. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment. Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437 [TBL] [Abstract][Full Text] [Related]
110. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705 [TBL] [Abstract][Full Text] [Related]
111. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients. Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC Clin Transpl; 2011; ():337-40. PubMed ID: 22755428 [TBL] [Abstract][Full Text] [Related]
112. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development. Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI Clin Transpl; 2006; ():241-53. PubMed ID: 18365382 [TBL] [Abstract][Full Text] [Related]
113. Association between PIRCHE-II scores and de novo allosensitization after reduction of immunosuppression during SARS-CoV-2 infection in kidney transplant recipients. Castrezana-Lopez K; Malchow R; Nilsson J; Kokkonen SM; Rho E; von Moos S; Mueller TF; Schachtner T Transpl Infect Dis; 2023 Apr; 25(2):e14052. PubMed ID: 36884207 [TBL] [Abstract][Full Text] [Related]
114. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Smith JD; Banner NR; Hamour IM; Ozawa M; Goh A; Robinson D; Terasaki PI; Rose ML Am J Transplant; 2011 Feb; 11(2):312-9. PubMed ID: 21219570 [TBL] [Abstract][Full Text] [Related]
115. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients. Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941 [TBL] [Abstract][Full Text] [Related]
116. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633 [TBL] [Abstract][Full Text] [Related]
117. Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol. Yazawa M; Cseprekal O; Helmick RA; Talwar M; Balaraman V; Podila PSB; Agbim UA; Maliakkal B; Fossey S; Satapathy SK; Sumida K; Kovesdy CP; Nair S; Eason JD; Molnar MZ Nephron; 2020; 144(3):126-137. PubMed ID: 32007998 [TBL] [Abstract][Full Text] [Related]
118. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Aubert V; Venetz JP; Pantaleo G; Pascual M Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474 [TBL] [Abstract][Full Text] [Related]